Abstract
Malignant melanoma, the deadliest form of skin cancer, is characterized by a predominant mutation in the BRAF gene1,2,3. Drugs that target tumours carrying this mutation have recently entered the clinic4,5,6,7. Accordingly, patients are routinely screened for mutations in this gene to determine whether they can benefit from this type of treatment. The current gold standard for mutation screening uses real-time polymerase chain reaction and sequencing methods8. Here we show that an assay based on microcantilever arrays can detect the mutation nanomechanically without amplification in total RNA samples isolated from melanoma cells. The assay is based on a BRAF-specific oligonucleotide probe. We detected mutant BRAF at a concentration of 500 pM in a 50-fold excess of the wild-type sequence. The method was able to distinguish melanoma cells carrying the mutation from wild-type cells using as little as 20 ng µl–1 of RNA material, without prior PCR amplification and use of labels.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
BMC Cancer Open Access 01 May 2020
-
Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action
Scientific Reports Open Access 03 February 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Roskoski, R. RAF protein-serine/threonine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 399, 313–317 (2010).
Gray-Schopfer, V. C., da Rocha Dias, S. & Marais, R. The role of B-RAF in melanoma. Cancer Metastasis Rev. 24, 165–183 (2005).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
Ribas, A. & Flaherty, K. T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nature Rev. Clin. Oncol. 8, 426–433 (2011).
Flaherty, K. T. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin. Exp. Metastasis 29, 841–846 (2012).
Ravnan, M. C. & Matalka, M. S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther. 34, 1474–1486 (2012).
Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012).
Halait, H. et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor Vemurafenib in metastatic melanoma. Diagn. Mol. Pathol. 21, 1–8 (2012).
Pratilas, C. A., Xing, F. & Solit, D. B. Targeting oncogenic BRAF in human cancer. Therapeut. Kinase Inhib. 355, 83–98 (2012).
Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305–2315 (2011).
Hinselwood, D. C., Abrahamsen, T. W. & Ekstrøm, P. O. BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis 26, 2553–2561 (2005).
Wu, C. C. et al. Label-free biosensing of a gene mutation using a silicon nanowire field-effect transistor. Biosens. Bioelectr. 25, 820–825 (2009).
Fang, Z. & Kelley, S. O. Direct electrocatalytic mRNA detection using PNA-nanowire sensors. Anal. Chem. 81, 612–617 (2009).
Fritz, J. et al. Translating biomolecular recognition into nanomechanics. Science 288, 316–318 (2000).
McKendry, R. et al. Multiple label-free biodetection and quantitative DNA-binding assays on a nanomechanical cantilever array. Proc. Natl Acad. Sci. USA 99, 9783–9788 (2002).
Biswal, S. L., Raorane, D., Chaiken, A., Birecki, H. & Majumdar, A. Nanomechanical detection of DNA melting on microcantilever surfaces. Anal. Chem. 78, 7104–7109 (2006).
Mertens, J. Label-free detection of DNA hybridization based on hydration-induced tension in nucleic acid films. Nature Nanotech. 3, 301–307 (2008).
Backmann, N. et al. A label-free immunosensor array using single-chain antibody fragments. Proc. Natl Acad. Sci. USA 102, 14587–14592 (2005).
Johansson, A., Blagoi, G. & Boisen, A. Polymeric cantilever-based biosensors with integrated readout. Appl. Phys. Lett. 89, 173505 (2006).
Braun, T. et al. Conformational change of bacteriorhodopsin quantitatively monitored by microcantilever sensors. Biophys. J. 90, 2970–2977 (2006).
Zhang, J. et al. Rapid and label-free nanomechanical detection of biomarker transcripts in human RNA. Nature Nanotech. 1, 214–220 (2006).
Lang, H. P., Hegner, M. & Gerber, Ch. Cantilever array sensors. Mater. Today 8, 30–36 (April, 2005).
Yang, M., Yau, H. C. M. & Chan, H. L. Adsorption kinetics and ligand-binding properties of thiol-modified double-stranded DNA on a gold surface. Langmuir 14, 6121–6129 (1998).
Nelson, B. P., Grimsrud, T. E., Liles, M. R., Goodman, R. M. & Corn, R. M. Surface plasmon resonance imaging measurements of DNA and RNA hybridization adsorption onto DNA microarrays. Anal. Chem. 73, 1–7 (2001).
Breslauer, K. J., Frank, R., Blocker, H. & Marky, L. A. Predicting DNA duplex stability from the base sequence. Proc. Natl Acad. Sci. USA 83, 3746–3750 (1986).
Barone, F., Cellai, L., Matzeu, M., Mazzei, F. & Pedone, F. DNA, RNA and hybrid RNA–DNA oligomers of identical sequence: structural and dynamic differences. Biophys. Chem. 86, 37–47 (2000).
Stuart, D. & Sellers, W. R. Linking somatic genetic alterations in cancer to therapeutics. Curr. Opin. Cell Biol. 21, 304–310 (2009).
Fritz, J. et al. Stress at the solid–liquid interface of self-assembled monolayers on gold investigated with a nanomechanical sensor. Langmuir 16, 9694–9696 (2000).
Valsesia, A. et al. Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS ONE 6, e18369 (2011).
Rimoldi, D. et al. Lack of BRAF mutations in uveal melanoma. Cancer Res. 63, 5712–5715 (2003).
Acknowledgements
The authors acknowledge ongoing support from M. Despont and U. Drechsler (IBM Research GmbH) in providing cantilever arrays. The authors also thank the National Center of Competence for Nanoscale Science (NCCR Nano), the Swiss Nano Institute (SNI), the NanoTera Program, the Cleven Foundation and the Swiss National Science Foundation for financial support. K. Muehlethaler is thanked for excellent technical assistance.
Author information
Authors and Affiliations
Contributions
F.H., D.R. and C.G. conceived the study. F.H. and D.R. designed the experiments and interpreted the data. F.H. performed and analysed the experiments. D.R. prepared DNA/RNA samples and cell lines. H.P.L. gold-coated the cantilever arrays. F.H., D.R., H.P.L., C.G. and N.B. wrote the manuscript. All authors discussed the results and commented on the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Huber, F., Lang, H., Backmann, N. et al. Direct detection of a BRAF mutation in total RNA from melanoma cells using cantilever arrays. Nature Nanotech 8, 125–129 (2013). https://doi.org/10.1038/nnano.2012.263
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nnano.2012.263
This article is cited by
-
Nanomechanical assay for ultrasensitive and rapid detection of SARS-CoV-2 based on peptide nucleic acid
Nano Research (2023)
-
Nanomechanical sensor for rapid and ultrasensitive detection of tumor markers in serum using nanobody
Nano Research (2022)
-
Scanning probe microscopy
Nature Reviews Methods Primers (2021)
-
Regulation of thermoelastic properties of concave-packaged DNA adsorption films and its relevant microcantilever detection signals
Acta Mechanica Sinica (2021)
-
Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
BMC Cancer (2020)